FDA Drug Safety Communication Warns That InvokanaⓇ and Other SGLT2 Inhibitors May Cause Serious Blood Condition
Invokana is a relatively new drug prescribed to treat type 2 diabetes. Although marketed as an effective new way for diabetics to manage their blood sugar, Invokana was soon linked to a dangerous condition known as ketoacidosis.
On May 15, 2015, the Food and Drug Administration released a safety announcement advising that Invokana and other SGLT2 inhibitors may be linked to kidney problems and ketoacidosis, which can result in coma or death. Other drugs in the SGLT2 class that the FDA listed as potentially dangerous are InvokametⓇ, FarxigaⓇ, Xigduo XRⓇ, JardianceⓇ, and GlyxambiⓇ.
Invokana, manufactured by Johnson & Johnson, is a dangerous pharmaceutical that has been linked to ketoacidosis, a dangerous condition caused by too much acid in the blood.
In March 2013, canagliflozin, which is the generic name of Invokana, became the first SGLT2 inhibitor to be approved by the FDA. SGLT2 inhibitors treat type 2 diabetes by causing the kidneys to eliminate blood glucose through urination.
In the first quarter of 2015 alone, Johnson & Johnson made over $278 in sales of the drug.
Pennsylvania, New Jersey and New York pharmaceutical attorneys at the Locks Law Firm are currently investigating potential claims.
If you or a loved one has used Invokana and experienced ketoacidosis, kidney damage, heart attack or any other harmful side effects, contact the Pennsylvania, New Jersey or New York Offices of the Locks Law Firm today. We urge you to contact us immediately as all claims are subject to strict requirements on when a case must be filed. Our experienced attorneys can provide information about filing an Invokana lawsuit during a free, confidential consultation and case evaluation.
